Design/Methods
Which drug(s) did this study evaluate?
Citalopram
Over what time period did this study recruit participants?
2007-2014 (7 years)
What was the approximate ratio of participants with bipolar 1 vs bipolar 2 disorder?
2:1
What clinical benefit did citalopram have on the acute or maintenance treatment of bipolar depression?
None. Citalopram, when added to standard mood stabilizers, did not have any clinically meaningful benefit vs. placebo in treatment of bipolar depression.
What/which diagnosis(es) did the participants in this study have?
Bipolar 1 or 2 disorder, current episode depressed
What type of clinical study was this?
Randomized double-blind placebo controlled
What was the most commonly used mood stabilizer in this study?
Lithium
In a study on patients with both ADHD and cocaine use disorder, what effect did mixed amphetamine salts have on marijuana use?
Increased weekly abstinence
How long were participants in their depressed mood episode when they entered the study?
8+ weeks
What was/were the primary acute outcomes?
MADRS over 6 weeks
Approximately what percentage of participants had rapid cycling?
28% (answer must be +/- 5%)
What happened to patients with rapid-cycling bipolar disorder on citalopram?
Worsening of manic symptoms
Which DSM version was used in this study?
IV
What were the secondary acute outcomes?
1) Clinical response: 50% decrease in MADRS scores
2) Clinical remission: MADRS score of 7 or less
Approximately what percentage of participants reported a history of substance use?
53% (answer must be +/- 5%)
How does exercise contribute to better mental health outcomes in patients with inflammatory disorders?
Number of participants who entered the trial
119
What was/were the main maintenance outcome(s) measured?
1) MDRS scores over 12 mo
2) Mania rating scale for the schedule of affective disorders and schizophrenia scores over 12 mo
What was the approximate mean dose of citalopram in the acute and maintenance phases: 10, 20, 30, 40, 50, 60 mg?
30
In comparing benzodiazepines, "Z-drugs", orexin antagonists, and melatonin/melatonin agonists for treatment of insomnia, which medications had the best profile in terms of efficacy, acceptability, and tolerability?